Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 60.22 USD 4.37% Market Closed
Market Cap: 7.4B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one HALO stock under the Base Case scenario is 64.58 USD. Compared to the current market price of 60.22 USD, Halozyme Therapeutics Inc is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HALO Relative Value
Base Case
64.58 USD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.3
P/S
P/S
Price to Sales
7.3
vs History
68
vs Industry
49
Median 3Y
7.3
Median 5Y
11.1
Industry
6.5
Forward
6.1
More Details
16.7
P/E
P/E
Price to Earnings
16.7
vs History
58
vs Industry
8
Median 3Y
18.4
Median 5Y
18.4
Industry
22
Forward
11.4
More Details
15.5
P/OCF
P/OCF
Price to OCF
15.5
vs History
58
vs Industry
11
Median 3Y
16.4
Median 5Y
16.6
Industry
18.4
More Details
16.1
P/FCFE
P/FCFE
Price to FCFE
16.1
vs History
17
vs Industry
9
Median 3Y
12.8
Median 5Y
12.3
Industry
23.4
More Details
20.4
P/B
P/B
Price to Book Value
20.4
vs History
80
vs Industry
3
Median 3Y
24.9
Median 5Y
35.2
Industry
2.2
More Details
8.2
EV/S
EV/S
Enterprise Value to Sales
8.2
vs History
73
vs Industry
39
Median 3Y
8.6
Median 5Y
11.7
Industry
7.1
Forward
6.8
More Details
9.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.7
vs History
84
vs Industry
38
Median 3Y
10.5
Median 5Y
14.5
Industry
8.7
More Details
13.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.2
vs History
77
vs Industry
10
Median 3Y
16.3
Median 5Y
17.7
Industry
3.3
Forward
10.5
More Details
15.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.1
vs History
80
vs Industry
9
Median 3Y
19.2
Median 5Y
19.8
Industry
3.1
Forward
12.1
More Details
17.4
EV/OCF
EV/OCF
Enterprise Value to OCF
17.4
vs History
57
vs Industry
9
Median 3Y
19.3
Median 5Y
19.1
Industry
4
More Details
17.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.8
vs History
57
vs Industry
7
Median 3Y
20
Median 5Y
19.4
Industry
2.6
More Details
5.7
EV/IC
EV/IC
Enterprise Value to IC
5.7
vs History
49
vs Industry
27
Median 3Y
4.9
Median 5Y
5.7
Industry
4.3
More Details

Multiples Across Competitors

HALO Competitors Multiples
Halozyme Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Halozyme Therapeutics Inc
NASDAQ:HALO
7.4B USD 7.3 16.7 13.2 15.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 901 062 -165 879.6 -201 430.7 -199 132.1
US
Abbvie Inc
NYSE:ABBV
309B USD 5.5 72.9 14.6 22.1
US
Amgen Inc
NASDAQ:AMGN
153.5B USD 4.6 37.5 15.4 27.3
US
Gilead Sciences Inc
NASDAQ:GILD
129.1B USD 4.5 269 10.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.4B USD 11.3 -232.3 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 018.5 -515.1 -560.9 -545.9
AU
CSL Ltd
ASX:CSL
115.1B AUD 4.8 26.6 16.4 20.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD 4.3 13.8 8.3 9.2
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -57.9
NL
argenx SE
XBRU:ARGX
30.5B EUR 15.8 41.7 306.4 -2 257.2
P/S Multiple
Revenue Growth P/S to Growth
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average P/S: 3 173 014.4
7.3
20%
0.4
FR
Pharnext SCA
OTC:PNEXF
34 901 062
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.5
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
2 018.5
N/A N/A
AU
CSL Ltd
ASX:CSL
4.8
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
7%
0.6
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
15.8
37%
0.4
P/E Multiple
Earnings Growth PEG
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average P/E: 68.3
16.7
31%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 879.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
72.9
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
37.5
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
269
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -232.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.1 N/A N/A
AU
CSL Ltd
ASX:CSL
26.6
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
41.7
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average EV/EBITDA: 51.3
13.2
26%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 430.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
14%
1
US
Amgen Inc
NASDAQ:AMGN
15.4
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.3
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
306.4
166%
1.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Halozyme Therapeutics Inc
NASDAQ:HALO
Average EV/EBIT: 19.1
15.1
28%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 132.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.9 N/A N/A
AU
CSL Ltd
ASX:CSL
20.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.2
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 257.2 N/A N/A

See Also

Summary
HALO intrinsic value, competitors valuation, and company profile.
DCF Valuation
HALO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HALO stock valuation using valuation multiples.
Wall Street Estimates
HALO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HALO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.